JW Holdings has received notification from the Korea Fair Trade Commission (KFTC) that it has been exempted from holding company regulations.

In a regulatory filing on the 30th, JW Holdings stated that it had filed for an exemption from holding company status on June 26, and received a response from the KFTC on June 30 confirming that the exemption was granted effective from the same date. The exemption from holding company status takes effect on June 26, 2026.

The company explained that while it has been exempted from holding company regulations under the Monopoly Regulation and Fair Trade Act, there are no changes to its main holding company operations, including brand royalty business and service provision.

Prior to the exemption, JW Holdings had six subsidiaries based on its ownership stakes (common shares) as follows:

• JW Pharmaceutical: 42.1%
• JW Novare: 30.7%
• JW Life Science: 43.0%
• JW Medical: 100%
• JW Household & Health Care: 100%
• Solidus Investment: 100%

Additionally, the company has four second-tier subsidiaries: C&C Pharmaceutical Research Institute, Saengmyeongnuri, JW Bioscience, and JW Chemtown.

The company noted that the date of fact confirmation for this filing is June 30, 2026, the date it received the official response letter from the KFTC regarding its exemption from holding company status.